| scholarly article | Q13442814 |
| P50 | author | Steven Rosenberg | Q2347448 |
| John Davies | Q59917096 | ||
| P2093 | author name string | Ling Zhang | |
| Nicholas P Restifo | |||
| Carylinda Serna | |||
| Richard A Morgan | |||
| Zhiya Yu | |||
| Christian S Hinrichs | |||
| P2860 | cites work | Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System® (RTS®) gene switch as gene therapy for the treatment of glioma. | Q54213332 |
| Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. | Q55086081 | ||
| Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer | Q57118558 | ||
| Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production | Q72686394 | ||
| Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo | Q73077128 | ||
| Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production | Q73774733 | ||
| Intratumoral injection of IL-12 plasmid DNA--results of a phase I/IB clinical trial | Q80448479 | ||
| Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy | Q81386256 | ||
| Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor | Q81498369 | ||
| The power and pitfalls of IL-12 | Q84067446 | ||
| A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers | Q90287047 | ||
| Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy | Q24596055 | ||
| Interleukin-12 and the regulation of innate resistance and adaptive immunity | Q29614602 | ||
| Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts | Q34109953 | ||
| Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment | Q34757266 | ||
| The B7-1 cytoplasmic tail enhances intracellular transport and mammalian cell surface display of chimeric proteins in the absence of a linear ER export motif | Q35000777 | ||
| A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response | Q35182795 | ||
| Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. | Q35563824 | ||
| IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. | Q35578622 | ||
| Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma | Q35613148 | ||
| Cancer immunotherapy using a membrane-bound interleukin-12 with B7-1 transmembrane and cytoplasmic domains. | Q35939476 | ||
| Evaluation of γ-retroviral vectors that mediate the inducible expression of IL-12 for clinical application | Q35982211 | ||
| Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. | Q36371632 | ||
| Immunotherapy of cancer by IL-12-based cytokine combinations | Q36724827 | ||
| Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy | Q36928580 | ||
| Collapse of the tumor stroma is triggered by IL-12 induction of Fas. | Q36984473 | ||
| IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments | Q37219974 | ||
| Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. | Q37389018 | ||
| Exploiting the curative potential of adoptive T-cell therapy for cancer | Q37576033 | ||
| Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma | Q38170498 | ||
| Immunogenicity of somatic mutations in human gastrointestinal cancers. | Q38823554 | ||
| Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer | Q40242985 | ||
| Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma | Q40507124 | ||
| Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. | Q45874251 | ||
| The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion | Q48337458 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P577 | publication date | 2020-01-01 | |
| P1433 | published in | Journal for Immunotherapy of Cancer | Q27725163 |
| P1476 | title | Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models | |
| P478 | volume | 8 |
Search more.